Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Astellas reports positive data from real-world Qutenza trials

Astellas reports positive data from real-world Qutenza trials

3rd September 2012

Astellas' patch-based therapy for peripheral neuropathic pain Qutenza has demonstrated a positive performance in a pair of real-world studies.

The eight percent capsaicin patch was shown in a Scandinavian observational study to deliver efficacy and tolerability in 211 non-diabetic patients with different peripheral neuropathic pain conditions.

Meanwhile, a separate trial held in the Czech Republic revealed that the product was able to provide quality of life improvements, while addressing concomitant medication concerns.

The most commonly reported side effects were transient and self-limiting application site reactions, such as mild to moderate pain and erythaema.

Dr Tomas Dolezal at the Institute of Health Economics and Technology Assessment in Prague said: "Our study showed there are high unmet needs in this patient population and the eight percent capsaicin patch offers an effective treatment for peripheral neuropathic pain, providing long-term pain relief and improved quality of life."

Last month, Astellas and partner Medivation published positive clinical trial data underlining the clinical benefits of the new prostate cancer therapy enzalutamide.ADNFCR-8000103-ID-801440762-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.